A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2023 Results assessing Assess Minimal Residual Disease after Ixazomib, Lenalidomide, Dexamethasone (Ird) Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients after 2 years on maintenance presented at the 28th Congress of the European Haematology Association
08 Dec 2020 Response rates and safety data presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
29 Jul 2020 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com